High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids

ABSTRACT The identification of effective biomarkers for early diagnosis, prognosis, and response to treatments remains a challenge in ovarian cancer (OC) research. Here, we present an unbiased high-throughput approach to profile ascitic fluid autoantibodies in order to obtain a tumor-specific antigen signature in OC. We first reported the reactivity of immunoglobulins (Igs) purified from OC patient ascites towards two different OC cell lines. Using a discovery set of Igs, we selected tumor-specific antigens from a phage display cDNA library. After biopanning, 700 proteins were expressed as fusion protein and used in protein array to enable large-scale immunoscreening with independent sets of cancer and noncancerous control. Finally, the selected antigens were validated by ELISA. The initial screening identified eight antigenic clones: CREB3, MRPL46, EXOSC10, BCOR, HMGN2, HIP1R, OLFM4, and KIAA1755. These antigens were all validated by ELISA in a study involving ascitic Igs from 153 patients (69 with OC, 34 with other cancers and 50 without cancer), with CREB3 showing the highest sensitivity (86.95%) and specificity (98%). Notably, we were able to identify an association between the tumor-associated (TA) antibody response and the response to a first-line tumor treatment (platinum-based chemotherapy). A stronger association was found by combining three antigens (BCOR, CREB3, and MRLP46) as a single antibody signature. Measurement of an ascitic fluid antibody response to multiple TA antigens may aid in the identification of new prognostic signatures in OC patients and shift attention to new potentially relevant targets.

[1]  I. Gram,et al.  Tumor‐associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation , 2018, International journal of cancer.

[2]  R. Kaaks,et al.  Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection. , 2017, Gynecologic oncology.

[3]  P. Bavi,et al.  Immuno-proteomic discovery of tumor tissue autoantigens identifies olfactomedin 4, CD11b, and integrin alpha-2 as markers of colorectal cancer with liver metastases. , 2017, Journal of proteomics.

[4]  K. Baggerly,et al.  Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer , 2017, Clinical Cancer Research.

[5]  C. Chapman,et al.  Autoantibodies: Opportunities for Early Cancer Detection. , 2017, Trends in cancer.

[6]  H. Yoshida,et al.  TFE3, HSP47, and CREB3 Pathways of the Mammalian Golgi Stress Response. , 2017, Cell structure and function.

[7]  A. Mäkitie,et al.  Nanofibrillar cellulose wound dressing in skin graft donor site treatment. , 2016, Journal of controlled release : official journal of the Controlled Release Society.

[8]  S. Miyano,et al.  Whole‐exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia , 2016, British journal of haematology.

[9]  R. Bast,et al.  Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer , 2016, Cancer Epidemiology, Biomarkers & Prevention.

[10]  T. Whiteside,et al.  Biological markers of prognosis, response to therapy and outcome in ovarian carcinoma , 2016, Expert review of molecular diagnostics.

[11]  Jillian T Henderson,et al.  Screening for Ovarian Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force , 2016, JAMA.

[12]  M. Ziman,et al.  Autoantibody Production in Cancer--The Humoral Immune Response toward Autologous Antigens in Cancer Patients. , 2016, Autoimmunity reviews.

[13]  T. Okita,et al.  Conflicting messages concerning current strategies against research misconduct in Japan: a call for ethical spontaneity , 2016, Journal of Medical Ethics.

[14]  M. Hsiao,et al.  Huntingtin-Interacting Protein-1 Is an Early-Stage Prognostic Biomarker of Lung Adenocarcinoma and Suppresses Metastasis via Akt-mediated Epithelial-Mesenchymal Transition. , 2016, American journal of respiratory and critical care medicine.

[15]  J. Ausió,et al.  HMGNs: The enhancer charmers , 2016, BioEssays : news and reviews in molecular, cellular and developmental biology.

[16]  Roland Eils,et al.  New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs , 2016, Cell.

[17]  M. Montico,et al.  Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis , 2015, PloS one.

[18]  Jian Huang,et al.  Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma. , 2015, World journal of hepatology.

[19]  Kaijuan Wang,et al.  Tumor associated antigens or anti-TAA autoantibodies as biomarkers in the diagnosis of ovarian cancer: a systematic review with meta-analysis , 2015, Expert review of molecular diagnostics.

[20]  H. Brenner,et al.  Systematic review: Serum autoantibodies in the early detection of gastric cancer , 2015, International journal of cancer.

[21]  R. Sidman,et al.  Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer , 2015, Proceedings of the National Academy of Sciences.

[22]  Alan Brown,et al.  Structure of the large ribosomal subunit from human mitochondria , 2014, Science.

[23]  F. Persichetti,et al.  An Air-well sparging minifermenter system for high-throughput protein production , 2014, Microbial Cell Factories.

[24]  Carlos Enrique Hirales Casillas,et al.  Current status of circulating protein biomarkers to aid the early detection of lung cancer , 2014 .

[25]  Phillip Stafford,et al.  Immunosignature system for diagnosis of cancer , 2014, Proceedings of the National Academy of Sciences.

[26]  H. Brenner,et al.  Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer. , 2014, Cancer letters.

[27]  E. Diamandis,et al.  Deciphering the ovarian cancer ascites fluid peptidome , 2014, Clinical Proteomics.

[28]  Akhilesh Pandey,et al.  Identification of head and neck squamous cell carcinoma biomarker candidates through proteomic analysis of cancer cell secretome. , 2013, Biochimica et biophysica acta.

[29]  N. Ahmed,et al.  Getting to Know Ovarian Cancer Ascites: Opportunities for Targeted Therapy-Based Translational Research , 2013, Front. Oncol..

[30]  Flavio Mignone,et al.  Profiling celiac disease antibody repertoire. , 2013, Clinical immunology.

[31]  Benjamin Haibe-Kains,et al.  curatedOvarianData: clinically annotated data for the ovarian cancer transcriptome , 2013, Database J. Biol. Databases Curation.

[32]  B. Monk,et al.  Latest research and treatment of advanced-stage epithelial ovarian cancer , 2013, Nature Reviews Clinical Oncology.

[33]  P. Rouanet,et al.  Identification and validation of new autoantibodies for the diagnosis of DCIS and node negative early‐stage breast cancers , 2013, International journal of cancer.

[34]  S. Kaye,et al.  Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research , 2013, Nature Reviews Cancer.

[35]  Yong-wen Huang,et al.  Screening and Identification of Biomarkers in Ascites Related to Intrinsic Chemoresistance of Serous Epithelial Ovarian Cancers , 2012, PloS one.

[36]  Kaitai Zhang,et al.  The ovarian cancer‐derived secretory/releasing proteome: A repertoire of tumor markers , 2012, Proteomics.

[37]  N. Heegaard,et al.  Circulating Antinuclear Antibodies in Patients with Pelvic Masses Are Associated with Malignancy and Decreased Survival , 2012, PloS one.

[38]  Kenneth P. Nephew,et al.  Rethinking ovarian cancer: recommendations for improving outcomes , 2011, Nature Reviews Cancer.

[39]  K. Kok,et al.  CREB3 subfamily transcription factors are not created equal: Recent insights from global analyses and animal models , 2011, Cell & Bioscience.

[40]  P. Hoffmann,et al.  Exploring the Immunoproteome for Ovarian Cancer Biomarker Discovery , 2011, International journal of molecular sciences.

[41]  C. Bokemeyer,et al.  Autoantibodies against tumor-related antigens: incidence and biologic significance. , 2010, Human immunology.

[42]  Jian-ying Zhang,et al.  Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors , 2010, Expert review of molecular diagnostics.

[43]  N. Halama,et al.  Seromic profiling of ovarian and pancreatic cancer , 2010, Proceedings of the National Academy of Sciences.

[44]  Luigi Biancone,et al.  Rapid interactome profiling by massive sequencing , 2010, Nucleic acids research.

[45]  U. Jaeger,et al.  Gene expression signature of chronic lymphocytic leukaemia with Trisomy 12 , 2009, European journal of clinical investigation.

[46]  N. Wentzensen,et al.  A systematic review of humoral immune responses against tumor antigens , 2009, Cancer Immunology, Immunotherapy.

[47]  E. Diamandis,et al.  Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers*S , 2009, Molecular & Cellular Proteomics.

[48]  E. Diamandis,et al.  Identifying novel autoantibody signatures in ovarian cancer using high-density protein microarrays. , 2009, Clinical biochemistry.

[49]  D. Ward,et al.  Diagnostic Markers for Early Detection of Ovarian Cancer , 2008, Clinical Cancer Research.

[50]  B. Ye,et al.  Use of a Combination of Approaches to Identify and Validate Relevant Tumor-Associated Antigens and Their Corresponding Autoantibodies in Ovarian Cancer Patients , 2008, Clinical Cancer Research.

[51]  Thorsten Verch,et al.  The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. , 2008, Gynecologic oncology.

[52]  S. Steinberg,et al.  Proteomic Analysis of Malignant Ovarian Cancer Effusions as a Tool for Biologic and Prognostic Profiling , 2006, Clinical Cancer Research.

[53]  Gerard Tromp,et al.  Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. , 2006, Cancer research.

[54]  Nuzhat Ahmed,et al.  Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer , 2005, Proteomics.

[55]  S. Meri,et al.  Ascitic complement system in ovarian cancer , 2005, British Journal of Cancer.

[56]  Steven J Skates,et al.  Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  Erkki Ruoslahti,et al.  A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[58]  X. Estivill,et al.  Cloning, Mapping and Expression Analysis of C15 or f4, a Novel Human Gene with Homology to the Yeast Mitochondrial Ribosomal Protein Yml30 Gene , 2001, DNA sequence : the journal of DNA sequencing and mapping.

[59]  E. Verdin,et al.  BCoR, a novel corepressor involved in BCL-6 repression. , 2000, Genes & development.

[60]  S. Orsulic,et al.  Ovarian Cancer , 1993, British Journal of Cancer.

[61]  V. Zurawski,et al.  Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: Relevance for early detection of ovarian cancer , 1988, International journal of cancer.

[62]  Audrey D. Doerr.  Atelier sur la recherche en administration publique au Canada , 1984 .

[63]  Carlos Enrique Hirales Casillas,et al.  Current status of circulating protein biomarkers to aid the early detection of lung cancer. , 2014, Future oncology.

[64]  S. Wotton,et al.  Overwinter population estimates of British waterbirds , 2011 .

[65]  G. Pruijn,et al.  The human exosome and disease. , 2011, Advances in experimental medicine and biology.

[66]  M. Chatterjee,et al.  Autoantibodies as biomarkers for ovarian cancer. , 2010, Cancer biomarkers : section A of Disease markers.

[67]  R. Marzari,et al.  Profiling the autoantibody repertoire by screening phage-displayed human cDNA libraries. , 2009, Methods in molecular biology.

[68]  A. Ignatchenko,et al.  A proteome resource of ovarian cancer ascites: integrated proteomic and bioinformatic analyses to identify putative biomarkers. , 2008, Journal of proteome research.